AGC Biologics is a global CDMO with extensive industry expertise in a variety of customizable services from scale-up to cGMP manufacturing of protein biologics. We have successfully manufactured 200+ products, using mammalian and microbial systems, from pre-clinical studies through clinical phases to commercial supply. By joining forces with our clients, we deliver on our mission to provide reliable drug development, and, to improve patients’ lives. One way that our company continues this legacy is by leveraging the expertise of our research and development (R&D) teams to assess and increase bioprocess capabilities.
AGC Biologics harnesses its R&D centers to bring modern and efficient approaches to development and manufacturing. Our dedicated R&D centers work alongside our teams at our seven global sites to determine the best strategies and procedures to push forward our mission of quality product delivery. Through this collaboration between our R&D teams, research and development scientists, and process development teams AGC Biologics ensures that innovation is constantly driving our processes, so we can provide the most up to date technology for early and late-stage clients. Our R&D center plays an integral part in the new offerings that will be coming to AGC Biologics platforms by focusing on increasing mass, increased speed to market, and overall process intensification.
Currently, our R&D scientists are working to enhance our bioprocess approach by applying new equipment and knowledge in areas like cell line, upstream, analytical, and downstream development to intensify our procedures while decreasing workflow timelines. AGC Biologics is utilizing the R&D division to increase our speed to market for clients. By implementing lean, innovative, and efficient practices, R&D initiatives are helping AGC Biologics provide advantageous offerings and superior results to customers.
The R&D team is currently implementing new strategies for high-throughput titer assessment to pinpoint high-producing monoclonal cell lines with very efficient timelines to maximize cell line development while trimming weeks off delivery.
Identifying quality cell lines in early-stage development will allow for a more targeted approach to assessing top producing candidates and decrease overall timelines. This helps provide clients with a variety of best options to move forward in the next stage of development. This type of new high throughput screening will also increase our ability to evaluate more monoclonal cell lines per project. Along with new instrumentation, new cell line platforms with innovative DNA integration systems are also being assessed to add to our client offerings to diversify the AGC Biologics R&D portfolio. 
